Qiagen (NYSE:QGEN) Sets New 12-Month Low – Should You Sell?

Qiagen N.V. (NYSE:QGEN) shares reached a new 52-week low on Wednesday . The stock traded as low as $33.78 and last traded at $33.9830, with a volume of 8088998 shares traded. The stock had previously closed at $38.09.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Preliminary Q1 results met adjusted diluted EPS outlook and reported net sales of about $492M (+2% reported), supporting near‑term profitability despite mixed sales trends. QIAGEN reports preliminary Q1 2026 results
• Neutral Sentiment: Unusually large options activity: traders bought ~6,107 call contracts on Monday (about +176% vs. average), indicating heightened speculative interest or hedging that can amplify intraday moves.
• Neutral Sentiment: Full Q1 earnings call transcript provides detail on end‑market weakness (lower QuantiFERON demand, cautious U.S. Life Sciences customers) and management’s rationale for the outlook. Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst/industry writeups that deep‑dive into Q1 metrics are circulating; they summarize mixed product trends and longer‑term implications but do not add new company disclosures. Qiagen’s Q1 2026 Earnings Report: A Deep Dive into Financial Performance and Market Trends
• Negative Sentiment: Guidance cut: Q2 EPS guided to ~0.60 (street ~0.62) and Q2 revenue to ~$523.3M (street ~$554M). Full‑year 2026 EPS guided to ~2.43 (street ~2.51) and revenue to ~$2.1B (street ~$2.2B). These misses are the primary near‑term driver of downward pressure on the stock.
• Negative Sentiment: Shareholder investigation announced: law firm Johnson Fistel is investigating potential claims against Qiagen executives, which raises legal/uncertainty risk and can increase selling pressure. Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $59.00 price objective on shares of Qiagen in a research note on Thursday, February 5th. Barclays set a $44.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a research note on Tuesday, April 14th. UBS Group set a $52.00 price objective on shares of Qiagen in a research note on Monday, February 9th. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the stock a “hold” rating in a research note on Friday, February 6th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research note on Friday, March 27th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $53.64.

Qiagen Trading Down 10.8%

The stock’s 50 day moving average price is $42.37 and its 200-day moving average price is $46.95. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $7.00 billion, a PE ratio of 16.85, a PEG ratio of 1.97 and a beta of 0.79.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. The company had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. Qiagen’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period last year, the company posted $0.61 earnings per share. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, sell-side analysts expect that Qiagen N.V. will post 2.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Qiagen

Several institutional investors have recently bought and sold shares of QGEN. Danske Bank A S purchased a new position in Qiagen during the third quarter valued at $36,000. Smartleaf Asset Management LLC grew its stake in Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after acquiring an additional 830 shares in the last quarter. Manchester Capital Management LLC purchased a new position in Qiagen during the fourth quarter valued at $42,000. Global Retirement Partners LLC grew its stake in Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after acquiring an additional 851 shares in the last quarter. Finally, Allworth Financial LP grew its stake in Qiagen by 23.2% during the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after acquiring an additional 256 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.